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Abstract.
Background: Parkinson’s disease (PD) patients using levodopa commonly develop dyskinesia and OFF episodes that reduce
quality of life.
Objective: Evaluate prevalence of troublesome dyskinesia and OFF through the day, assessed by 30-minute intervals, as well
as the mean number and duration of troublesome dyskinesia and OFF episodes, transitions between PD states, and effects of
Gocovri® (amantadine) extended release capsules on these episodes.
Methods: Evaluate diary data from pooled Gocovri phase 3, placebo-controlled trials—analyzed for 17 hours following
wake-up—at baseline and week 12.
Results: Diaries were evaluable for 162 patients. At baseline, 67% of patients woke up OFF, with prevalence decreasing to 13%
at 2 hours and then remaining relatively steady at ∼12% (range, 6–17%) across half-hour intervals thereafter. Troublesome
dyskinesia prevalence rose steadily from 5% to 24% over the first 2 hours, then fluctuated between 20% and 44% through
the rest of the waking day. At baseline, patients experienced a mean of 3.0 daily episodes of troublesome dyskinesia (average
duration 2.0 hours each), and 2.2 daily episodes of OFF (average duration 1.1 hour each). At week 12, Gocovri-treated
patients showed greater reductions than placebo in troublesome dyskinesia and OFF episodes per day (treatment difference:
–1.0 episodes and –0.4 episodes, respectively) and average episode duration (treatment difference: –0.6 hours and –0.3 hours,
respectively). Mean duration of individual episodes of ON without troublesome dyskinesia (Good ON) increased by 5.0
hours for Gocovri, compared with 2.0 hours for placebo. Patients taking Gocovri experienced 2.2 fewer transitions between
states than patients taking placebo.
∗ Correspondence to: Robert A. Hauser, MD, MBA, Department of Neurology, Parkinson’s Disease and Movement Disorders
Center, Parkinson Foundation Center of Excellence, University

of South Florida, 4001 East Fletcher Avenue, Tampa, FL 33596,
USA. Tel.: +1 813 396 0768; Fax: +1 813 905 9829; E-mail:
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Conclusions: Troublesome dyskinesia and OFF occurred in the morning and throughout the waking day. Gocovri-treated
patients experienced fewer, shorter episodes of both troublesome dyskinesia and OFF, thereby increasing the duration of
continuous Good ON episodes and reducing the frequency of transitions between motor states.
Keywords: Amantadine, delayed-action preparations, double-blind method, dyskinesias, OFF, episodes, humans, levodopa,
Parkinson disease, transitions, treatment

INTRODUCTION
Patients on chronic levodopa therapy for Parkinson’s disease (PD) commonly develop OFF and
dyskinesia as PD progresses, often with significant
impact on daily life [1–5]. Such patients are typically faced with a medication management trade-off,
in which adjusting the dosage or dosing frequency
of levodopa or adjunctive drugs may reduce OFF
time but worsen dyskinesia, or may reduce dyskinesia but result in increased OFF time [6–8]. To our
knowledge, there have to date been no investigations
specifically evaluating the temporal pattern of OFF
and dyskinesia through the day. An understanding
of these timing patterns, might offer new insights
into the expression of motor complications, thereby
improving PD symptom management and associated
quality of life (QOL) [9]. In addition, prior studies of
adjunctive medications in PD have focused on total
daily OFF time and total daily time with troublesome
dyskinesia, and there has been little or no information provided regarding effects on the number and
duration of individual episodes of these states.
Gocovri® (amantadine) extended release capsules
(Adamas Pharmaceuticals, Inc.) is an orally administered high-dose, extended-release formulation of
amantadine approved for the treatment of dyskinesia
in patients with PD taking levodopa-based therapy.
Amantadine acts as an uncompetitive antagonist of
the N-methyl-D-aspartate glutamate receptor, which
is thought to be overstimulated in the striatum of dyskinetic PD patients [10, 11]. Gocovri is designed
to be dosed once-daily at bedtime. Delayed drug
release and slow rise in plasma concentrations provide high amantadine concentrations in the morning
and throughout the waking day with lower evening
exposure [12]. In each of 2 published, double-blind,
placebo-controlled phase 3 trials (EASE LID [13]
and EASE LID 3 [14]), patients with dyskinesia
completed PD home diaries [15] at baseline (before
exposure to study drug) and at treatment time points,
including week 12 (primary endpoint). In both
trials, Gocovri provided a significant reduction in
dyskinesia as assessed using the Unified Dyskinesia
Rating Scale (UDysRS) [16] as well as a significant

reduction in total daily OFF time and troublesome
dyskinesia (as assessed by PD home diaries), resulting in a mean increase in total daily ON time without
troublesome dyskinesia (also known as Good ON
time) [13,14,16].
Here we have applied novel analyses to the pooled
diary data from these pivotal trials to: 1) map baseline population prevalence of dyskinesia and OFF
by 30-minute intervals through the day; 2) assess
the individual mean number and duration of daily
episodes of troublesome dyskinesia and OFF, as well
as the number of daily transitions between PD states;
and 3) evaluate the effects of Gocovri on these PD
patterns.
METHODS
Study designs and participants
The EASE LID trial [13] (ClinicalTrials.gov identifier: NCT02136914) was conducted at 44 North
American sites between May 2014 and July 2015,
and the EASE LID 3 trial [14] (NCT02274766) at 39
sites in the US and Western Europe between October
2014 and December 2015. All patients were required
to be experiencing at least one hour/day (2 half-hour
intervals) of ON time with troublesome dyskinesia
between 9 am and 4 pm, on the two days preceding
treatment initiation, as documented by entries in PD
home diaries [15]. The dyskinesia was required to be
causing at least mild functional impairment, as documented at screening and baseline by a score ≥ 2 on
item 4.2 of the Movement Disorder Society–Unified
Parkinson’s Disease Rating Scale (MDS-UPDRS)
[17]. Enrolled patients were randomized in a 1 : 1
ratio to double-blind Gocovri or placebo once daily at
bedtime. Gocovri was initiated at 137 mg/day (equivalent to 170 mg of amantadine HCl) for the first week
and titrated to 274 mg/day (equivalent to 340 mg of
amantadine HCl) thereafter.
Efﬁcacy measures and analyses
In both trials, the primary outcome was change
from baseline in UDysRS total score, as assessed at
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week 12. In each trial, this outcome was analyzed in
the modified intent-to-treat (mITT) population, comprising all randomized patients who were exposed to
study drug, and underwent at least 1 post-baseline
UDysRS assessment. The present analyses include
all patients with evaluable PD home-diary data for a
2-day period at baseline and at week 12, as defined
in each trial’s Statistical Analysis Plan (see Supplementary Material).
In PD home diaries, patients categorize their predominant motor state during each half-hour interval
of the 24-hour day as 1 of 5 categories: ON with
no dyskinesia, ON with non-troublesome dyskinesia, ON with troublesome dyskinesia, OFF, or asleep
[15]. For the present analyses, we combined the first
2 categories (ON with no dyskinesia and ON with
non-troublesome dyskinesia) into a single category
of ON without troublesome dyskinesia, or “Good
ON.” At baseline, and independently at week 12, each
patient’s wake-up time was defined as the start of the
first of 4 consecutive half-hour intervals not reported
as asleep on the second day of diary-keeping, beginning at or after 3 am (as rated in the diary entry for
3 : 30 am). Because each 24-hour diary started at 6
am, when some patients were already awake, the second day’s data were utilized for all analyses. The
17-hour time span following wake-up time could then
be plotted by predominant status during each halfhour interval, for descriptive assessment at baseline
and at week 12, across these visits, and across treatment groups. An “episode” was defined as time spent
in a PD-diary state (ON without troublesome dyskinesia, ON with troublesome dyskinesia, or OFF)
before transitioning to any other state, thereby beginning a new episode. “Asleep” during the day was not
considered a transition, but its time was not reallocated to other episodes. Time periods during which
sleep interrupted a single category of PD state were
counted as two episodes of that state. Descriptive
statistics were compiled for total number of transitions between each motor state, as well as the number
of each type of episode, their average duration, duration of the first such episode, and for week 12 data,
the proportions of patients with no dyskinesia or OFF
episodes (a 17-hour waking day free of ON time with
troublesome dyskinesia, free of OFF time, or free of
both).
For calculation of the treatment difference between
Gocovri vs. placebo at week 12, a Mixed-Effect
Model Repeated Measure (MMRM) analysis was
used with change from baseline as the dependent variable and baseline value as a covariate. The model,
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which was generated in SAS version 9.4 (SAS Institute Inc., Cary, North Carolina), included categorical
effects for treatment group, study, and visit (Weeks
2, 8, and 12), and the interaction between treatment
group and visit. The treatment differences between
Gocovri and placebo for the mean changes from baseline through week 12 in the number of transitions per
day, total ON time with troublesome dyskinesia, OFF
time, and ON time without troublesome dyskinesia
were calculated using a Wilcoxon two-sample test at
the 0.05 significance level.
Ethical conduct
Each study was conducted in accordance with the
Declaration of Helsinki and with Good Clinical Practice guidelines. Before the start of each study, each
study site received approval from an institutional
review board, research ethics board, or independent ethics committee; before any study procedures,
written informed consent was obtained from each
patient.
RESULTS
Study participants
Across the EASE LID [13] and EASE LID 3
[14] studies, the pooled mITT population comprised
196 patients (100 for Gocovri and 96 for placebo).
Among them, 162 patients (77 for Gocovri and 85 for
placebo) provided evaluable diary data both at baseline and at week 12 (pooled “diary population”). Of
the 34 (17.3%) patients who did not meet criteria for
inclusion in this diary analysis, 28 patients (14.3%)
dropped out prior to week 12 and 6 patients (3.0%)
failed to provide evaluable diaries or had incomplete
diaries at baseline (Supplementary Table 1).
Baseline characteristics of the overall pooled mITT
population have been reported previously [18]; baseline characteristics of the pooled diary population
used for this analysis are summarized by treatment
group in Table 1 and resembled the overall mITT population [18]. On average, diary population patients
were 64.5 years of age (range, 34–82) and had a
9.9-year duration of PD (range, 1.0–26.8), a 7.6-year
duration of levodopa treatment (range, 1.2–20.3), a
3.8-year duration of dyskinesia (range, 0.1–14.0), 5.0
hours/day of ON time with troublesome dyskinesia
(range, 0.0–13.0), and 2.8 hours/day of OFF time
(range, 0.0–10.0).
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Table 1
Baseline demographic and PD characteristics, by treatment group (pooled diary population)
Variable
Age (y), mean [range]
Sex, n (%)
Male
Female
Race, n (%)
White
Other
Duration of PD (y), mean
[range]
Duration of levodopa
treatment (y), mean [range]
Duration of dyskinesia (y),
mean [range]
ON time with troublesome
dyskinesia (h/d),a,b mean
[range]
ON time without troublesome
dyskinesia (h/d),b,c mean
[range]
OFF time (h/d),b mean
[range]
MDS-UPDRS item 4.2
score,d mean [range]
UDysRS total score, mean
[range]

Gocovri
(n = 77)

Placebo
(n = 85)

All Patients
(N = 162)

63.5 [34–79]

65.4 [42–82]

64.5 [34–82]

41 (53.2%)
36 (46.8%)

50 (58.8%)
35 (41.2%)

91 (56.2%)
71 (43.8%)

74 (96.1%)
3 (3.9%)
10.3 [2.2–26.8]

79 (92.9%)
6 (7.1%)
9.5 [1.0–19.4]

153 (94.4%)
9 (5.6%)
9.9 [1.0–26.8]

8.0 [1.4–20.3]

7.3 [1.2–18.3]

7.6 [1.2–20.3]

4.2 [0.1–14.0]

3.4 [0.3–11.3]

3.8 [0.1–14.0]

4.8 [0.0a –12.0]

5.2 [1.0–13.0]

5.0 [0.0a –13.0]

8.5 [0.0–15.0]

8.1 [1.0–15.0]

8.3 [0.0–15.0]

3.1 [0.0–10.0]

2.6 [0.0–9.0]

2.8 [0.0–10.0]

2.6 [2–4]

2.5 [2–4]

2.5 [2–4]

41.7 [10–76]

39.1 [8–62]

40.4 [8–76]

a One

patient with no troublesome dyskinesia was included as a protocol deviation. b Two-day average,
from 24-hour PD home diaries. c ON time without troublesome dyskinesia is the sum of ON time without
dyskinesia and ON time with non-troublesome dyskinesia. d Functional impact of dyskinesias, rated from
0 (none) to 4 (severe). h/d, hours per day; MDS-UPDRS, Movement Disorder Society–Unified Parkinson’s
Disease Rating Scale; mITT, modified intent-to-treat; PD, Parkinson’s disease; UDysRS, Unified Dyskinesia
Rating Scale; y, years.

Baseline daily pattern of PD motor complications
In order to understand the temporal pattern of
dyskinesia and OFF, measured in 30-minute intervals among patients with PD, we determined the
proportion of patients experiencing each PD state
over the 17-hour waking day at baseline (Fig. 1A).
At baseline, the proportion of patients experiencing
troublesome dyskinesia rose from 5% to 24% over the
2 hours following morning awakening and then fluctuated between 20% and 44% through hour 15, before
decreasing as patients fell asleep. The proportion of
patients in the OFF state was highest (67%) upon
morning awakening, decreased to 13% by hour 2, and
then was relatively steady at ∼12% (range, 6%–17%)
until onset of sleep. The proportions of patients experiencing ON without troublesome dyskinesia (Good
ON) rose from 28% at wake-up to 63% by 2 hours,
varied between 40% and 62% through hour 15, and
then decreased as patients went to sleep (Fig. 1A).

The proportions of patients in each diary state
are charted across half-hour intervals, by treatment
group, at baseline and week 12 in Fig. 1B. For
Gocovri–treated patients, an average of 24% more
patients experienced Good ON during any half-hour
period, at week 12 compared with baseline. This
increase was due to mean reductions in both the
percentages of patients who experienced ON with
troublesome dyskinesia (–20%) and OFF (–4%). In
contrast, for the placebo group, an average of 8%
more patients experienced Good ON during any halfhour period at week 12 compared with baseline. This
was due to mean reductions in the percentages of
patients reporting troublesome dyskinesia (–11%) but
not OFF (+3%). At week 12, for 32 of the 34 measured half-hour waking intervals (94%), a greater
percentage of patients treated with Gocovri experienced Good ON compared with placebo; for 24
of these intervals (70.6%) this prevalence difference
favored Gocovri by >10%.
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Fig. 1. Proportion of patients in each PD state during each half-hour interval of the waking day, based on PD home-diary data. A. At baseline
(pooled diary population; N = 162). B. By treatment group at baseline and at 12 weeks (pooled diary population; n = 77 for Gocovri and n = 85
for placebo). C. Example of individual patient experiences. For each treatment group, the sample patient was chosen for display who most
closely represented the treatment group median values using the following hierarchy: 1) patient with median value for change in transitions;
if more than one patient, then 2) select those with transition count at baseline closest to the group median; then 3) select the patient whose
change in ON without troublesome dyskinesia was closest to the group median. Diary plots of episodes and transitions are shown for all
patients, graphed in “heat map” fashion, in the Supplemental Material.
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Table 2
PD state episodes as derived from diary data, by treatment group (pooled diary population)

Variable
Baseline
Transitions
Number of transitions, mean (SD)
ON with troublesome dyskinesia
Number of episodes, mean (SD)
Duration of an episode (h), mean (SD)
Duration of first episodea (h), mean (SD)
OFF
Number of episodes, mean (SD)
Duration of an episode (h), mean (SD)
Duration of first episodea (h), mean (SD)
ON without troublesome dyskinesia
Number of episodes, mean (SD)
Duration of an episode (h), mean (SD)
Duration of first episodea (hours), mean (SD)

Gocovri (n = 77)
Week 12
Change

Baseline

Placebo (n = 85)
Week 12
Change

All (N = 162)
Baseline

8.6 (4.5)

4.4 (4.0)

–4.2 (4.5)

7.6 (3.5)

5.6 (3.5)

–2.0 (3.4)

8.1 (4.0)

3.0 (1.6)
1.9 (1.8)
1.9 (1.9)

0.9 (1.4)
0.7 (1.2)
0.8 (1.3)

–2.1 (1.8)
–1.2 (2.2)
–1.2 (2.3)

2.9 (1.4)
2.1 (2.0)
2.1 (2.1)

1.8 (1.5)
1.5 (1.8)
1.4 (1.8)

–1.1 (1.7)
–0.6 (2.2)
–0.7 (2.3)

3.0 (1.5)
2.0 (1.9)
2.0 (2.0)

2.4 (1.8)
1.0 (0.8)
1.0 (0.8)

1.9 (1.8)
0.9 (0.7)
0.8 (0.7)

–0.5 (1.6)
–0.2 (0.8)
–0.2 (0.9)

2.0 (1.7)
1.1 (1.0)
1.1 (1.1)

1.8 (1.5)
1.3 (1.0)
1.1 (0.9)

–0.1 (1.4)
+0.1 (1.1)
0.0 (1.2)

2.2 (1.8)
1.1 (0.9)
1.1 (1.0)

4.2 (2.0)
2.3 (1.7)
2.1 (1.8)

2.6 (1.6)
7.3 (5.5)
7.3 (5.8)

–1.6 (2.2)
+ 5.0 (5.1)
+5.2 (5.3)

3.7 (1.4)
2.4 (1.5)
2.3 (1.8)

3.0 (1.5)
4.4 (4.1)
4.3 (4.3)

–0.8 (1.7)
+ 2.0 (3.7)
+2.0 (4.0)

4.0 (1.8)
2.4 (1.6)
2.2 (1.8)

a “Duration

of first episode” describes, for all patients, the duration of the first recorded occurrence of that diary state, regardless of whether
or not it was the diary state upon wake-up. h, hours; PD, Parkinson’s disease; SD, standard deviation.

Dyskinesia and OFF episodes - characteristics
and transitions throughout the day
During the waking day, diary-population patients
experienced, on average, 8.1 transitions between
clinical-state episodes (other than sleep). At baseline,
an average day included 3.0 episodes of ON with troublesome dyskinesia, each lasting an average of 2.0
hours, and 2.2 episodes of OFF, each lasting an average of 1.1 hours. Patients also averaged 4.0 episodes
of Good ON, each lasting an average of 2.4 hours.
Diary plots for each patient can be found in the Supplementary Material, and similar to those in Fig. 1C,
illustrate the erratic nature of these episodes as they
occur throughout the day.
Characteristics of episodes of troublesome dyskinesia and OFF, and numbers of daily PD state
transitions, are summarized by treatment group in
Table 2. In the Gocovri group, the average duration
of each episode of ON with troublesome dyskinesia
decreased by 1.2 hours, compared with 0.6 hours for
placebo, and the average duration of each episode
of OFF decreased by 0.2 hours, compared with an
increase of 0.1 hours for placebo. For both OFF
and troublesome dyskinesia, the average number of
episodes and the average duration of the first such
episode also showed greater decreases for Gocovri
than for placebo. Episodes of Good ON exhibited
corresponding increases in duration. The mean duration of individual episodes of Good ON increased
by 5.0 hours in the Gocovri group compared to 2.0
hours in the placebo group. Notably, the duration of
the first episode of the day of Good ON increased

by an average of 5.2 hours in the Gocovri group,
compared with 2.0 hours for placebo.
On average, diary population patients receiving
Gocovri experienced 4.2 (49%) fewer transitions
between episode states at week 12 than at baseline
(4.4 vs 8.6 per day), compared with 2.0 (26%) fewer
transitions (5.6 vs 7.6 per day) among patients receiving placebo, representing a Gocovri over placebo
treatment difference of –2.2 transitions per day
(P = 0.004). Example diary days from Gocovri- and
placebo-treated patients representing the median
reductions in the number of episode transitions for
their respective groups are illustrated in Fig. 1C.
The proportion of patients reporting no episodes of
ON with troublesome dyskinesia [all ON time is
Good ON time] at week 12 was 57.1% for Gocovri,
compared with 24.7% for placebo; the proportion
reporting no OFF time was 27.3%, compared with
20.0%, respectively; and the proportion reporting
neither troublesome dyskinesia nor OFF time was
19.5%, compared with 3.5%, respectively. Figure 2
shows, for all patients, the distribution of baseline to
week 12 change values for the duration of Good ON
episodes, the duration of the first such episode, and
the total number of transitions between diary state
episodes. For each measure, the distributions show a
large leftward shift with Gocovri treatment, indicative
of improvement compared with placebo.
Effect of Gocovri on cumulative hours of
troublesome dyskinesia and OFF per day
In order to ensure that the subpopulation of patients
providing evaluable diary data was consistent with the
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Fig. 2. Distribution of individual patient changes from baseline to week 12 in derived PD diary measures. Each bar represents an individual
patient from the pooled diary population (N = 162); Bars show the magnitude of change at week 12. Bars showing a change of 0 have been
thickened slightly. A. Each patient’s mean change in duration of ON without troublesome dyskinesia (Good ON) episodes. B. Duration of
first episode of Good ON. C. Number of transitions between PD diary states.

overall population from the pivotal trials, we analyzed
the cumulative effect of Gocovri on PD states across
the entire day. The mean changes across the entire day
from baseline at week 12 for the 3 states are shown
in Supplementary Table 2. The LS mean treatment
difference vs placebo showed a decrease in OFF time
of 1.2 hours (95% CI –1.73, –0.57, P < 0.001) and
a decrease in ON time with troublesome dyskinesia
of 1.5 hours (95% CI –2.27, –0.67, P < 0.001). The
increase in Good ON time was 2.5 hours (95% CI

1.56, 3.53, P < 0.001). All values are consistent with
previously reported pooled findings from EASE LID
and EASE LID 3 [18, 19].
Safety
For the overall pooled population, the safety profile
of Gocovri has been reported previously [18]. For the
diary subpopulation, the safety profile is presented in
Table 3. During the full duration of study-drug expo-
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Table 3
Adverse events during study-drug exposurea by
treatment group (pooled diary population)
Incidence, n (%)
Summary
Any AE leading
to study-drug
discontinuation
By preferred termb
Dizziness
Constipation
Hallucinationc
Dry mouth
Peripheral edema
Fall
Urinary tract
infection

Gocovri
(n = 77)

Placebo
(n = 85)

3 (3.9%)

1 (1.2%)

12 (15.6%)
11 (14.3%)
11 (14.3%)
10 (13.0%)
10 (13.0%)
9 (11.7%)
8 (10.4%)

1 (1.2%)
3 (3.5%)
2 (2.4%)
1 (1.2%)
1 (1.2%)
7 (8.2%)
4 (4.7%)

a Up

to 25 weeks in EASE LID, and up to 13 weeks
in EASE LID 3. b The list includes all preferred terms
with an incidence ≥ 10.0% among patients receiving
Gocovri. c Includes visual and auditory hallucination.
AE, adverse event.

sure (up to 25 weeks in EASE LID and up to 13 weeks
in EASE LID 3), the adverse events (AEs) reported
in ≥ 10.0% of diary-population patients receiving
Gocovri were dizziness, constipation, hallucination
(visual or auditory), dry mouth, peripheral edema,
fall, and urinary tract infection. Overall, AE frequencies in the diary subpopulation resembled those in
the full pooled population [18]. However, because the
subpopulation excludes patients who lacked week 12
data, it is enriched for tolerability and showed a lower
proportion of patients with AEs leading to discontinuation relative to the full pooled population, at 3.9%
vs 20.0% [18].
DISCUSSION
Analyses of diary data in clinical trials of medications for PD patients with motor fluctuations and/or
dyskinesia have typically focused on measures of
total daily OFF time, total daily ON time without
troublesome dyskinesia, and total daily ON time with
troublesome dyskinesia. Here we provide a more
in-depth analysis of diary data and present novel
approaches that, to our knowledge, have not been
reported for adjunctive medications previously. We
first evaluated the population-level pattern of troublesome dyskinesia and OFF prevalence through the day,
assessed by half-hour intervals. We then evaluated
the effect of Gocovri on troublesome dyskinesia and
OFF through the day using the same novel analytical
method. We wanted to know whether, for example,

troublesome dyskinesia (on a population basis) tends
to build through the day and is more prevalent in the
late afternoon and evening compared to the morning
or whether troublesome dyskinesia was essentially
evenly distributed throughout the day. Our results
indicate that, at the study population level, troublesome dyskinesia increased in the first hours following
wake-up and was then prevalent throughout the day
(20%–44%), whereas there was a peak of OFF early
in the morning, followed by a lower (6–17%) distribution throughout the rest of the waking day. We
also wanted to discern whether Gocovri exerted its
benefit during a specific part of the day, or whether it
provided benefit throughout the day. Results suggest
that it provided benefit throughout the day, consistent
with its pharmacokinetic profile [12].
In a second set of analyses, we evaluated individual episodes of troublesome dyskinesia, OFF, and
Good ON (ON without troublesome dyskinesia),
which could extend through multiple 30-minute intervals. We evaluated the mean number of these daily
episodes and their mean duration, both at baseline
and following treatment with Gocovri or placebo. To
our knowledge, this is the first time such an analysis has been performed for an adjunctive medication
in PD. We also evaluated the number of transitions
between diary states at baseline and following treatment. Results indicated that Gocovri reduced both the
number and duration of individual episodes of troublesome dyskinesia and OFF through the day, as well
as the number of daily transitions between PD motor
states.
While studies have clearly identified an inverse
relationship between QOL and daily amount of OFF
time and troublesome dyskinesia [4, 19], there is little
information available about the relationship between
number of transitions between PD states and QOL. It
seems likely that longer duration of episodes of ON
without troublesome dyskinesia, coupled with fewer
transitions, would lead to a better, more predictable
day and would allow for better activity planning and
engagement, although this remains to be rigorously
studied.
An important limitation of the present work is that
it is comprised of post-hoc analyses of pre-existing
databases. In addition, diary data were derived from
patients reporting at least mild dyskinesia at baseline (per MDS-UPDRS item 4.2) and at least one
hour/day of troublesome dyskinesia (per PD home
diary) between the hours of 9 am and 4 pm. Thus,
the analyses may not reflect a more generalized PD
population not selected for timing, type, or severity of
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dyskinesia or OFF episodes. However, patients with
evening dyskinesia were not excluded, provided they
also had dyskinesia between 9 am and 4 pm. In fact,
the percentages of patients reporting dyskinesia late
in the day (but before sleep) were similar to the percentages reporting dyskinesia earlier in the day (see
Fig. 1). Another limitation is that the study’s measures
of clinical states did not include tools for capturing
the intensity of each state (except for categorizing the
presence of dyskinesia as troublesome or not). In the
future, wearable sensors and other types of monitors
may provide continuous monitoring through the day
and allow more sensitive assessment of mild motor
fluctuations and dyskinesia. Lastly, our analyses only
included the 83% of enrolled patients who provided
evaluable diaries at baseline and week 12 (the “diary
population”). They do not include those who withdrew prematurely, or who provided non-evaluable
diaries at baseline or week 12. Nonetheless, baseline
demographics and diary state efficacy outcomes were
found to be similar between the diary subpopulation
and overall pooled population.
These analyses expand the knowledge of temporal
patterns of clinical states in PD. The overall pattern of dyskinesia that we identified was a relatively
steady population prevalence, from hours 2 through
15, without clear peaks or troughs. There was a peak
of OFF prevalence seen in the first hour after waking,
and subsequently, a relatively steady lower prevalence from hours 2 through 15, without clear peaks
or troughs. Our results also demonstrated a treatment
effect of Gocovri for dyskinesia and OFF throughout
the waking day.
These novel analyses of diary data can be applied
to other therapies and provide additional insights
regarding the patient experience through the day. We
anticipate there will be increasing interest in these
types of analyses as wearable sensors and other objective PD monitoring devices are introduced that can
provide data that are continuously obtained through
the day. Evaluating the pattern of an individual
patient’s clinical states and seeking therapies whose
pharmacokinetics and clinical effects best match the
individual’s needs for amelioration of dyskinesia and
OFF through the day can be a facet of personalized
medicine that may lead to better clinical management
and improved patient satisfaction.
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